Fig. 1: Associations between selected metabolic biomarkers and incident colorectal cancer risk in the UK biobank cohort.
Hazard ratios (HR) and 95% confidence intervals (CIs) for 1-standard deviation (SD) increase in biomarker levels were estimated after adjusting for sex, race, educational attainment, fasting time, self-reported use of cholesterol-lowering medications, colorectal cancer family history and colorectal cancer screening history. *P-value < 1×10−3. **P-value < 1 × 10-4. ***P-value < 1 × 10−5. Apo-A1 apolipoprotein A1, Apo-B apolipoprotein B, DHA docosahexaenoic acid, FA fatty acids, FAw3 omega-3 fatty acids, FAw6 omega-6 fatty acids, HDL high-density lipoproteins, HDL-D high-density lipoprotein particle diameter, IDL intermediate-density lipoproteins, L large, LA linoleic acid, LDL low-density lipoproteins, LDL-D low-density lipoprotein particle diameter, LP lipoprotein, M medium, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids, S small, SFA saturated fatty acids, VLDL very low-density lipoproteins, VLDL-D very low-density lipoprotein particle diameter, XL very large, XS very small, XXL extremely large.
